Green Thumb Industries (GTBIF) Income from Non-Controlling Interests (2019 - 2026)
Green Thumb Industries (GTBIF) posted Income from Non-Controlling Interests of -$350000.0 for Q1 2026, down 316.67% on a QoQ basis from -$84000.0 in Q4 2025, and down 468.42% year-over-year from $95000.0 in Q1 2025.
Green Thumb Industries (GTBIF) Income from Non-Controlling Interests (2019 - 2026) Analysis & Trends
Green Thumb Industries' Income from Non-Controlling Interests history runs 8 years deep, the most recent figure standing at -$350000.0 for Q1 2026.
- Quarterly Income from Non-Controlling Interests fell 468.42% year-over-year to -$350000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.5 million (up 146.36% YoY) and the FY2025 annual result came in at $1.9 million, up 147.53% from the prior year.
- Income from Non-Controlling Interests was -$350000.0 for Q1 2026 at Green Thumb Industries, down from -$84000.0 in the prior quarter.
- Across five years, Income from Non-Controlling Interests topped out at $1.4 million in Q2 2025 and bottomed at -$350000.0 in Q1 2026.
- A 5-year average of $302823.5 and a median of $290000.0 in 2023 frame the typical range for Income from Non-Controlling Interests.
- Annual changes were most pronounced in 2025 — Income from Non-Controlling Interests surged 568.45% — and 2026, when it slumped 468.42%.
- Green Thumb Industries' Income from Non-Controlling Interests stood at $317000.0 in 2022, then retreated by 5.05% to $301000.0 in 2023, then slumped by 58.47% to $125000.0 in 2024, then tumbled by 167.2% to -$84000.0 in 2025, then slumped by 316.67% to -$350000.0 in 2026.
- Business Quant data shows GTBIF's Income from Non-Controlling Interests at -$350000.0 in Q1 2026, -$84000.0 in Q4 2025, and $513000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | - |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | 395,346.10 |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | - |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | -12.70 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | - |
| 10 | Green Thumb Industries | 1.63 Bn | 1.29 Bn | 143.65 Mn | -350,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -350,000.00 |
| Dec 31, 2025 | -84,000.00 |
| Sep 30, 2025 | 513,000.00 |
| Jun 30, 2025 | 1.38 Mn |
| Mar 31, 2025 | 95,000.00 |
| Dec 31, 2024 | 125,000.00 |
| Sep 30, 2024 | 165,000.00 |
| Jun 30, 2024 | 206,000.00 |
| Mar 31, 2024 | 272,000.00 |
| Dec 31, 2023 | 301,000.00 |
| Sep 30, 2023 | 295,000.00 |
| Jun 30, 2023 | 290,000.00 |
| Mar 31, 2023 | 266,000.00 |
| Dec 31, 2022 | 317,000.00 |
| Sep 30, 2022 | 319,000.00 |
| Jun 30, 2022 | 294,000.00 |
| Mar 31, 2022 | 747,000.00 |
| Dec 31, 2021 | 1.24 Mn |
| Sep 30, 2021 | 1.38 Mn |
| Jun 30, 2021 | 1.22 Mn |